91 related articles for article (PubMed ID: 15985759)
1. Influence of the cyto-protective agent amifostine on the pharmacokinetics of low-dose Paclitaxel.
Juan O; Rocher A; Sánchez A; Sánchez JJ; Alberola V
Chemotherapy; 2005 Jul; 51(4):200-5. PubMed ID: 15985759
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and metabolism of paclitaxel after polychemotherapy with the cytoprotective agent amifostine.
Czejka M; Schueller J; Eder I; Reznicek G; Kraule C; Zeleni U; Freitag R
Anticancer Res; 2000; 20(5C):3871-7. PubMed ID: 11268469
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
5. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
6. Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index.
Ozcan Arican G
Cancer Chemother Pharmacol; 2005 Aug; 56(2):221-9. PubMed ID: 15838658
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Fidias P; Supko JG; Martins R; Boral A; Carey R; Grossbard M; Shapiro G; Ostler P; Lucca J; Johnson BE; Skarin A; Lynch TJ
Clin Cancer Res; 2001 Dec; 7(12):3942-9. PubMed ID: 11751486
[TBL] [Abstract][Full Text] [Related]
8. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
[TBL] [Abstract][Full Text] [Related]
10. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
Akerley W; Herndon JE; Egorin MJ; Lyss AP; Kindler HL; Savarese DM; Sherman CA; Rosen DM; Hollis D; Ratain MJ; Green MR
Cancer; 2003 May; 97(10):2480-6. PubMed ID: 12733147
[TBL] [Abstract][Full Text] [Related]
11. A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA
Cancer Chemother Pharmacol; 2012 Mar; 69(3):825-34. PubMed ID: 22057853
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Goffin JR; Anderson IC; Supko JG; Eder JP; Shapiro GI; Lynch TJ; Shipp M; Johnson BE; Skarin AT
Clin Cancer Res; 2005 May; 11(9):3417-24. PubMed ID: 15867243
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
14. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
Choy H; Yee L; Cole BF
Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
[TBL] [Abstract][Full Text] [Related]
15. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of a 1-h paclitaxel infusion.
Mross K; Holländer N; Hauns B; Schumacher M; Maier-Lenz H
Cancer Chemother Pharmacol; 2000; 45(6):463-70. PubMed ID: 10854133
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
[TBL] [Abstract][Full Text] [Related]
18. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials.
Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L
Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Van den Brande J; Nannan Panday VR; Hoekman K; Rosing H; Huijskes RV; Verheijen RH; Beijnen JH; Vermorken JB
Am J Clin Oncol; 2001 Aug; 24(4):401-3. PubMed ID: 11474273
[TBL] [Abstract][Full Text] [Related]
20. Thoracic radiation therapy and concomitant low-dose daily paclitaxel in non-small cell lung cancer: a phase I study.
Gobitti C; Franchin G; Minatel E; Gigante M; Basso B; Bujor L; Trovò MG
Oncol Rep; 2005 Dec; 14(6):1647-53. PubMed ID: 16273271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
